Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amifampridine Phosphate in Ambulatory Spinal Muscular Atrophy Type 3
2017-004600-22Phase 2Completed
- Sponsor
- Catalyst Pharmaceuticals
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of amifampridine in Spinal muscular atrophy type 3 (SMA3) and spinal muscular atrophy (SMA) (2 arms), sponsored by Catalyst Pharmaceuticals. Primary endpoint: Change in HFMSE score from baseline. Started Apr 2021; status: completed.
02
Drugs
amifampridine
03
Conditions
Spinal muscular atrophy type 3 (SMA3)spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on 2017-004600-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004600-22.